NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

Executive Summary

• NurExone Biologic announced new laboratory data showing its proprietary BM‑MSC‑derived exosomes reduce IL‑6 by >86 % and TNF‑α by >62 % in LPS‑stimulated RAW 264.7 macrophages, outperforming a commercially available exosome control.
• The anti‑inflammatory effect is dose‑dependent, with meaningful reductions observed even at the lowest concentrations tested.
• Management highlighted that these results strengthen the analytical framework for ExoPTEN and support the company’s broader platform for scalable, regulatory‑ready exosome therapeutics.

Key Details

• Test System: RAW 264.7 macrophage cells stimulated with lipopolysaccharide (LPS) to induce inflammation.
• Treatments Compared: NurExone BM‑MSC extracellular vesicles (EVs) vs. commercial BM‑MSC EV product, across a range of concentrations.
• IL‑6 Reduction: NurExone EVs lowered IL‑6 levels by >86 % relative to untreated LPS‑stimulated control at all tested concentrations; commercial EVs showed no significant change.
• TNF‑α Reduction: Dose‑dependent decrease with NurExone EVs, achieving >62 % reduction at the highest concentration; commercial EVs produced no meaningful effect.
• Statistical Analysis: One‑way ANOVA with Tukey’s multiple comparisons; significance levels reported as P < 0.01 () and P* < 0.0001 (*).
• Implications Stated by Management:
• Enhances batch‑to‑batch consistency, quality, and regulatory readiness for ExoPTEN.
• Demonstrates platform robustness for exosome‑based drug delivery across indications.
• Forward‑Looking Statements: Company expects the anti‑inflammatory activity to support regenerative pathways and aid progression toward clinical trials, though acknowledges typical early‑stage development risks.

Notable Quotes

“These laboratory results show that our exosomes suppress inflammation more effectively than untreated cells and commercial alternatives… with stronger effects as the doses increase.” – Dr. Tali Kizhner, Director of R&D
“We are building an analytical framework to understand and quantify the true biological complexity of exosome‑based therapeutics… essential for advancing our own drug programs and establishing a reliable, scalable platform.” – Dr. Lior Shaltiel, CEO

Materiality Assessment: Non‑Material – Positive (pre‑clinical data that is encouraging but does not yet impact financial results or regulatory status).